Difference between revisions of "Team:CPU CHINA"
| Line 26: | Line 26: | ||
<center class="pagee pagee0" id="dyk"> | <center class="pagee pagee0" id="dyk"> | ||
| + | <p><br> <br></p> | ||
<p><br> <br></p> | <p><br> <br></p> | ||
<p><br> <br></p> | <p><br> <br></p> | ||
| Line 32: | Line 33: | ||
<center class="pagee pagee1"> | <center class="pagee pagee1"> | ||
| + | <p><br> <br></p> | ||
| + | <p><br> <br></p> | ||
<p><br> <br></p> | <p><br> <br></p> | ||
<h5 style="padding: 0px; margin: 5px;">Our HEAD-Treg</h5> | <h5 style="padding: 0px; margin: 5px;">Our HEAD-Treg</h5> | ||
Revision as of 15:17, 1 November 2017
Our HEAD-Treg
Description
Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease.
It is of great essence to develop a novel cell-targeted therapy for RA
because there is no radical cure
for RA for the time being.
To solve the problems existing in the current treatment of RA, we design and build a brand new immunotherapy.
FOXP3+ regulatory T cells(Tregs), which can suppress and regulate immune reactions, are modified
utilizing a lentiviral vector system to express a chimeric antigen receptor(CAR) targeting inflammatory cells associated with RA.
Meanwhile, we insert the Syn-Notch receptor to activate the functional stability pathway of Tregs in the
inflammatory environment, which enables them to play their role of immunosuppression in lesions more
efficiently and more stably.
These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect.
